Page 2 - ஜ்ப் இரசாயனங்கள் மருந்துகள் லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(Bloomberg) India’s sharp surge in Covid-19 cases will not prevent the country’s markets from setting a record for initial public offerings in 2021, as a cohort of technology companies make their much-anticipated debuts later in the year, according to UBS Group AG. Last year companies amassed $4.6 billion from IPOs, according to data compiled by Bloomberg, and Anuj Kapoor, head of investment banking at UBS India, believes the figure will be easily eclipsed. “I would say we will surpass twice the money we raised in 2020 through IPOs,” Kapoor said. Before the arrival of the coronavirus pandemic’s second wave, India’s markets were full of optimism. So far in 2021, IPOs in India have raised nearly $3 billion, the best start to the year since 2018, the data show. The activity was aided by ample liquidity, with foreign investors as well as retail stock-pickers looking for new ideas to invest in, Kapoor said. Read More: SPACs Look to India for Next Wave of Targets, Nomura Says T

Anuj kapoorZomato ltdPiramal pharma ltdCarlyle group incJb chemicals pharmaceuticals ltdNext waveNykaae retail pvtBloomberg newsHire more investmentCarlyle groupPiramal pharmaBusiness generalஅனுஜ் கபூர்பிரமல் பார்மா லிமிடெட்கார்லைல் குழு இன்க்ஜ்ப் இரசாயனங்கள் மருந்துகள் லிமிடெட்